Chinese-based Innovent Biologics and HUTCHMED are eyeing approval for their cancer combination after a joint Phase II/III ...

Some cancer cells have what are called checkpoint ... People in this trial got either Keytruda plus lenvatinib, lenvatinib plus everolimus, or sunitinib. There were 1,069 people in this study ...

Fruzaqla given in combination with sintilimab slowed progression in the second line for those with locally advanced or metastatic renal cell carcinoma.

Ipsen/Exelixis' Cabometyx once-daily tablet has been approved in the EU in patients with advanced renal cell carcinoma following ... with Novartis' Afinitor (everolimus). The commission granted ...

The care of patients with metastatic renal-cell carcinoma (mRCC ... temsirolimus and everolimus. Approximately three-quarters of renal cancers are clear-cell carcinomas, and most tumors of ...

Hutchmed China, alongside Innovent Biologics, announced on Wednesday that the FRUSICA-2 phase two and three clinical trial ...

An expert discusses how medical professionals counsel patients on adverse event (AE) risks with tyrosine kinase inhibitors ...

which evaluated sintilimab in combination with fruquintinib as second-line treatment for locally advanced or metastatic renal cell carcinoma (RCC) in China, has met its primary endpoint of ...